Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine

Liaocheng People's Hospital

Status and phase: Not yet enrolling; Phase 1

Conditions: Traditional Chinese Medicine; Helicobacter Pylori Infection; Eradication

Treatments: Drug: Bismuth quadruplicate group; Drug: Ban xia xie xin Decoction and bismuth quadruplicate group

Study type: Interventional

Funder types: Other

Identifiers

NCT05586464

123456

Details and patient eligibility

About

This study is a prospective randomized case-control study. Six hundred patients who were firstly diagnosed as Helicobacter pylori infection will be selected, and then randomly assigned into case group and control group. Patients in control group take bismuth quadruplicate for 14 days. Patients in case group take Ban xia xie xin Decoction and bismuth agent quadruple for 14 days. Exhalation test or stool Helicobacter pylori antigen detection were used to assess the eradication rate of Helicobacter pylori 30 days (the 45th day) after treatment; Adverse reactions were evaluated on the first day (15th day) and the 30th day (45th day) after treatment. The eradication rate of Helicobacter pylori and the adverse drug reactions during the medication will be evaluated. The effect of Ban xia xie xin Decoction and bismuth quadruple based on furazolidone on the eradication of helicobacter pylori infection will be explored.

Full description

Helicobacter pylori is a primary carcinogen of gastric cancer. Helicobacter pylori infection rate is about 50% in China. Helicobacter pylori infection should be eradicated unless there are countervailing factors. The bismuth agent quadruple (PPI+bismuth pectin+2 kinds of antibiotics) has eradicated the first line therapy of H. Pylori infection. The rise of antibiotic resistance rate leads to the decline of eradication rate of H. pylori. Traditional Chinese medicine played an important role in the treatment of H. pylori infection. This study explored the application of Ban xia xie xin Decoction and bismuth agent quadruple based on furazolidone in the role of the eradication of H. Pylori infection. This study is a prospective randomized case-control study. Six hundred patients who were firstly diagnosed as Helicobacter pylori infection will be selected, and then randomly assigned into case group and control group. The case group was named as Traditional Chinese Medicine group. Patients in the case group will take Ban xia xie xin Decoction and bismuth quadruplicate for 14 days. The control group was named as bismuth quadruplicate group. Patients in the control group will take bismuth quadruplicate for 14 days. Bismuth quadruplicate includes esomeprazole (nexium 20mg bid), amoxicillin (amoxicillin 1.0 bid), furazolidone (100mg bid) and pectin bismuth gel (150mg qid). Ban xia xie xin Decoction includes 10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube. One dose in the morning and one dose in the evening, and take after meals. Exhalation test or stool Helicobacter pylori antigen detection were used to assess the eradication rate of Helicobacter pylori 30 days (the 45th day) after treatment; Adverse reactions were evaluated on the first day (15th day) and the 30th day (45th day) after treatment. The eradication rate of Helicobacter pylori and the adverse drug reactions during the medication will be evaluated. The effect of Ban xia xie xin Decoction and bismuth quadruple on the eradication of helicobacter pylori infection will be explored.

Enrollment: 600 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. H. Pylori infection: Carbon13/Carbon14-urea breath test positive or rapid urease test positive or gastric mucosal tissue pathological section positive immunohistochemistry staining or gastric mucosal tissue positive H. pylori culture or fecal Positive detection of H. pylori antigen.
2. No history of H. Pylori infection eradication therapy;
3. Age 18-70 years
4. H.Pylori infection check was completed within 1 month before the start of the study.

Exclusion criteria

1. Pregnant or lactating women;
2. There are other serious diseases that affect the evaluation of this study, such as severe coronary heart disease, liver disease, kidney disease, chronic obstructive pulmonary disease, malignant tumor, and psychosocial diseases;
3. History of major or complex gastrointestinal surgery;
4. Those who are allergic to the drugs used in this study;
5. Patients participate other drug studies within 3 months;
6. Patients can not cooperate with the experimenter.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)

---

600 participants in 2 patient groups

Traditional Chinese Medicine group

Experimental group

Description:

Patients in the case group will take Ban xia xie xin Decoction and bismuth quadruplicate for 14 days. H. pylori was rechecked one month after drug withdrawal, and H. pylori clearance rate and adverse reactions were observed in the reorganized patients. Ban xia xie xin Decoction includes 10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube. One dose in the morning and one dose in the evening, and take after meals. Bismuth quadruplicate includes esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).

Treatment:

Drug: Ban xia xie xin Decoction and bismuth quadruplicate group

Bismuth quadruplicate group

Active Comparator group

Description:

Patients in the control group will take bismuth quadruplicate for 14 days. H. pylori was rechecked one month after drug withdrawal, and H. pylori clearance rate and adverse reactions were observed in the reorganized patients. Bismuth quadruplicate includes esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).

Treatment:

Drug: Bismuth quadruplicate group